An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390)

Andrea N. Leaf, Donna Neuberg, Edward L. Schwartz, Scott Wadler, Paul S. Ritch, Janice P. Dutcher, George L. Adams

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The purpose of this study was to determine the efficacy and toxicity of amonafide in unresectable or recurrent head and neck cancer and to determine if the degree of toxicity with amonafide correlated with the acetylator phenotype of the patient. Thirty patients were registered on the study and received amonafide, 300 mg/m2, over two hours each day for five consecutive days every 21 days. There was one partial response (3%) which lasted four months. The dose-limiting toxicity was myelosuppression. Acetylator phenotype was determined prior to treatment using HPLC to quantitate caffeine metabolites in urine samples after administration of caffeine. This pharmacokinetic evaluation was performed in 21 patients and revealed that (17/21) 81% of the patients were slow acetylators and 19% of the patients were rapid acetylators. No association was found between acetylator phenotype and toxicity in our patient population. Based on this study, it appears that amonafide given at 300 mg/m2 for 5 consecutive days every 21 days is not active in squamous cell carcinoma of the head and neck, and that acetylator status does not correlate with toxicity.

Original languageEnglish (US)
Pages (from-to)165-172
Number of pages8
JournalInvestigational New Drugs
Volume15
Issue number2
DOIs
StatePublished - 1997

Fingerprint

amonafide
Neck
Head
Carcinoma
Caffeine
Phenotype
Head and Neck Neoplasms
Pharmacokinetics
High Pressure Liquid Chromatography
Urine

Keywords

  • Amonafide
  • Head and neck neoplasms

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390). / Leaf, Andrea N.; Neuberg, Donna; Schwartz, Edward L.; Wadler, Scott; Ritch, Paul S.; Dutcher, Janice P.; Adams, George L.

In: Investigational New Drugs, Vol. 15, No. 2, 1997, p. 165-172.

Research output: Contribution to journalArticle

Leaf, Andrea N. ; Neuberg, Donna ; Schwartz, Edward L. ; Wadler, Scott ; Ritch, Paul S. ; Dutcher, Janice P. ; Adams, George L. / An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390). In: Investigational New Drugs. 1997 ; Vol. 15, No. 2. pp. 165-172.
@article{794c1a1957524a4ea7db1a49c039d78b,
title = "An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390)",
abstract = "The purpose of this study was to determine the efficacy and toxicity of amonafide in unresectable or recurrent head and neck cancer and to determine if the degree of toxicity with amonafide correlated with the acetylator phenotype of the patient. Thirty patients were registered on the study and received amonafide, 300 mg/m2, over two hours each day for five consecutive days every 21 days. There was one partial response (3{\%}) which lasted four months. The dose-limiting toxicity was myelosuppression. Acetylator phenotype was determined prior to treatment using HPLC to quantitate caffeine metabolites in urine samples after administration of caffeine. This pharmacokinetic evaluation was performed in 21 patients and revealed that (17/21) 81{\%} of the patients were slow acetylators and 19{\%} of the patients were rapid acetylators. No association was found between acetylator phenotype and toxicity in our patient population. Based on this study, it appears that amonafide given at 300 mg/m2 for 5 consecutive days every 21 days is not active in squamous cell carcinoma of the head and neck, and that acetylator status does not correlate with toxicity.",
keywords = "Amonafide, Head and neck neoplasms",
author = "Leaf, {Andrea N.} and Donna Neuberg and Schwartz, {Edward L.} and Scott Wadler and Ritch, {Paul S.} and Dutcher, {Janice P.} and Adams, {George L.}",
year = "1997",
doi = "10.1023/A:1005823703909",
language = "English (US)",
volume = "15",
pages = "165--172",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390)

AU - Leaf, Andrea N.

AU - Neuberg, Donna

AU - Schwartz, Edward L.

AU - Wadler, Scott

AU - Ritch, Paul S.

AU - Dutcher, Janice P.

AU - Adams, George L.

PY - 1997

Y1 - 1997

N2 - The purpose of this study was to determine the efficacy and toxicity of amonafide in unresectable or recurrent head and neck cancer and to determine if the degree of toxicity with amonafide correlated with the acetylator phenotype of the patient. Thirty patients were registered on the study and received amonafide, 300 mg/m2, over two hours each day for five consecutive days every 21 days. There was one partial response (3%) which lasted four months. The dose-limiting toxicity was myelosuppression. Acetylator phenotype was determined prior to treatment using HPLC to quantitate caffeine metabolites in urine samples after administration of caffeine. This pharmacokinetic evaluation was performed in 21 patients and revealed that (17/21) 81% of the patients were slow acetylators and 19% of the patients were rapid acetylators. No association was found between acetylator phenotype and toxicity in our patient population. Based on this study, it appears that amonafide given at 300 mg/m2 for 5 consecutive days every 21 days is not active in squamous cell carcinoma of the head and neck, and that acetylator status does not correlate with toxicity.

AB - The purpose of this study was to determine the efficacy and toxicity of amonafide in unresectable or recurrent head and neck cancer and to determine if the degree of toxicity with amonafide correlated with the acetylator phenotype of the patient. Thirty patients were registered on the study and received amonafide, 300 mg/m2, over two hours each day for five consecutive days every 21 days. There was one partial response (3%) which lasted four months. The dose-limiting toxicity was myelosuppression. Acetylator phenotype was determined prior to treatment using HPLC to quantitate caffeine metabolites in urine samples after administration of caffeine. This pharmacokinetic evaluation was performed in 21 patients and revealed that (17/21) 81% of the patients were slow acetylators and 19% of the patients were rapid acetylators. No association was found between acetylator phenotype and toxicity in our patient population. Based on this study, it appears that amonafide given at 300 mg/m2 for 5 consecutive days every 21 days is not active in squamous cell carcinoma of the head and neck, and that acetylator status does not correlate with toxicity.

KW - Amonafide

KW - Head and neck neoplasms

UR - http://www.scopus.com/inward/record.url?scp=0030994444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030994444&partnerID=8YFLogxK

U2 - 10.1023/A:1005823703909

DO - 10.1023/A:1005823703909

M3 - Article

C2 - 9220297

AN - SCOPUS:0030994444

VL - 15

SP - 165

EP - 172

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -